FOXO4-dri mastery course
Unit 8 of 11
The Senolytic Landscape
How FOXO4-DRI fits among competing approaches to senescent cell clearance.
a growing field
FOXO4-DRI is one of several approaches to clearing senescent cells, but it is not the most clinically advanced. Understanding where it sits in the senolytic landscape -- and what distinguishes it from small-molecule competitors -- is essential for reading the evidence with appropriate context.
Senolytic Comparison Matrix
Compare key senolytic agents across mechanism, selectivity, evidence stage, and delivery route.
senolytic comparison matrix
senolytic landscape snapshot
How the major senolytic approaches compare.
dasatinib + quercetin
small molecules, most clinically advanced senolytic combo. multiple human trials completed. broad-spectrum but lower selectivity than peptide approaches.
navitoclax (ABT-263)
Bcl-2 family inhibitor. potent senolytic activity but significant side effect: thrombocytopenia (platelet destruction). limits clinical use outside of oncology.
FOXO4-DRI
peptide-based, p53-mediated apoptosis. potentially more selective than small molecules because it targets a specific protein-protein interaction. preclinical only.
fisetin
natural flavonoid. oral, cheap, widely available. senolytic activity in cell culture, but human bioavailability is extremely poor. Mayo Clinic trials ongoing.
FOXO4-DRI is not the most clinically advanced senolytic. dasatinib + quercetin has been tested in multiple human trials. FOXO4-DRI's advantage is mechanistic selectivity, but it has not yet entered human testing and its clinical profile is entirely unknown.
key terms
Definitions for this unit.
S
A compound that selectively kills senescent cells while sparing healthy cells. The term was coined by Kirkland and Tchkonia at the Mayo Clinic. Senolytics work by disabling the anti-apoptotic defenses that allow senescent cells to resist programmed cell death.
B
a family of proteins that regulate apoptosis. Bcl-2 and Bcl-xL are anti-apoptotic -- they keep cells alive. senescent cells upregulate these proteins to resist death. navitoclax inhibits them, tipping the balance toward apoptosis. FOXO4-DRI uses a different mechanism (p53 liberation) instead.
T
Dangerous reduction in blood platelet count, causing bleeding risk. This is the major dose-limiting side effect of navitoclax (ABT-263) because platelets depend on Bcl-xL for survival. FOXO4-DRI's p53-mediated mechanism should avoid this problem since it does not target the Bcl-2 family.
S
The ability of a drug to affect senescent cells without harming healthy cells. FOXO4-DRI targets the FOXO4-p53 interaction, which is enriched in senescent cells. Small-molecule senolytics like dasatinib have broader kinase inhibition that can affect non-senescent cells.
F
A class of plant-derived polyphenolic compounds. Quercetin and fisetin are flavonoids with senolytic activity in cell culture. Their advantage is oral availability and low cost, but human bioavailability is generally poor and the senolytic mechanism may require concentrations difficult to achieve orally.